» Articles » PMID: 20137867

Evaluation of Late Adverse Events in Long-term Wilms' Tumor Survivors

Abstract

Purpose: To evaluate the prevalence and severity of adverse events (AEs) and treatment-related risk factors in long-term Wilms' tumor (WT) survivors, with special attention to radiotherapy.

Methods And Materials: The single-center study cohort consisted of 185 WT survivors treated between 1966 and 1996, who survived at least 5 years after diagnosis. All survivors were invited to a late-effects clinic for medical assessment of AEs. AEs were graded for severity in a standardized manner. Detailed radiotherapy data enabled us to calculate the equivalent dose in 2 Gy fractions (EQD(2)) to compare radiation doses in a uniform way. Risk factors were evaluated with multivariate logistic regression analysis.

Results: Medical follow-up was complete for 98% of survivors (median follow-up, 18.9 years; median attained age, 22.9 years); 123 survivors had 462 AEs, of which 392 had Grade 1 or 2 events. Radiotherapy to flank/abdomen increased the risk of any AE (OR, 1.08 Gy(-1) [CI, 1.04-1.13]). Furthermore, radiotherapy to flank/abdomen was associated with orthopedic events (OR, 1.09 Gy(-1) [CI, 1.05-1.13]) and second tumors (OR, 1.11 Gy(-1) [CI, 1.03-1.19]). Chest irradiation increased the risk of pulmonary events (OR, 1.14 Gy(-1) [CI, 1.06-1.21]). Both flank/abdominal and chest irradiation were associated with cardiovascular events (OR, 1.05 Gy(-1) [CI, 1.00-1.10], OR, 1.06 Gy(-1) [CI, 1.01-1.12]) and tissue hypoplasia (OR, 1.17 Gy(-1) [CI, 1.10-1.24], OR 1.10 Gy(-1) [CI, 1.03-1.18]).

Conclusion: The majority of AEs, overall as well as in irradiated survivors, were mild to moderate. Nevertheless, the large amount of AEs emphasizes the importance of follow-up programs for WT survivors.

Citing Articles

Injectable polypeptide-polysaccharide depot for preventing postoperative tumor recurrence by concurrent chemotherapy and brachytherapy.

Fan J, Cai X, Gui H, Mei L, Xu W, Wang D Mater Today Bio. 2024; 28:101219.

PMID: 39280112 PMC: 11399797. DOI: 10.1016/j.mtbio.2024.101219.


Precision based approach to tailoring radiotherapy in the multidisciplinary management of pediatric central nervous system tumors.

Phuong C, Qiu B, Mueller S, Braunstein S J Natl Cancer Cent. 2024; 3(2):141-149.

PMID: 39035723 PMC: 11256719. DOI: 10.1016/j.jncc.2023.03.001.


Dosimetric Advantage of Combined IMRT for Whole Lung and Abdomen Irradiation for Wilms Tumor.

Chaballout B, McComas K, Khattab M, Seymore G, Martinez S, Luo G Adv Radiat Oncol. 2024; 9(8):101527.

PMID: 38993191 PMC: 11233888. DOI: 10.1016/j.adro.2024.101527.


Incidence and prevalence of musculoskeletal health conditions in survivors of childhood and adolescent cancers: A report from the Swiss childhood cancer survivor study.

Christen S, Roser K, Mader L, Otth M, Scheinemann K, Sommer G Cancer Med. 2024; 13(8):e7204.

PMID: 38650581 PMC: 11036073. DOI: 10.1002/cam4.7204.


MRI-based inter- and intrafraction motion analysis of the pancreatic tail and spleen as preparation for adaptive MRI-guided radiotherapy in neuroblastoma.

Van Ommen F, le Quellenec G, Willemsen-Bosman M, van Noesel M, van den Heuvel-Eibrink M, Seravalli E Radiat Oncol. 2023; 18(1):160.

PMID: 37784151 PMC: 10546671. DOI: 10.1186/s13014-023-02347-9.